Cancer history drove the strongest signal in genetic cancer risk testing engagement
In a nationally representative sample of U.S. adults, personal cancer history emerged as the clearest predictor of genetic cancer risk testing engagement. The 2023 National Health Interview Survey captured a spectrum of participation, from no engagement at all to provider discussion, test uptake, or both. Most adults, 90.5%, reported no engagement, while 3.3% reported both discussion and testing, 4.3% reported discussion only, and 1.9% reported uptake only.
Personal cancer history was associated with every engagement category, and the association was strongest when both discussion and uptake were present. Adjusted analyses showed an odds ratio of 5.08 for both discussion and testing, compared with no engagement. Discussion only was also strongly linked to cancer history, with an adjusted odds ratio of 2.66, and uptake only carried an adjusted odds ratio of 1.57. Those estimates point to a familiar clinical pattern: a prior cancer diagnosis often triggers renewed attention to inherited susceptibility, especially when family history, tumor features, or recurrence concerns raise the possibility of an underlying germline driver.
A single diagnosis can change the entire testing conversation.
Rural residence altered the pathway more than the final odds
Residential context mattered, but not in a simple way. Rural residence was associated with lower odds of both engagement and uptake only in unadjusted models, suggesting an access gap at first glance. After adjustment for sociodemographic and health-related covariates, those associations weakened, indicating that measured differences in age, insurance, education, health status, or related factors may explain part of the raw rural-urban contrast.
Even so, the interaction between cancer history and rurality remained statistically significant in both the unadjusted model and the adjusted model, with p values of 0.008 and 0.005. In practical terms, the effect of a cancer history on testing engagement was not identical across residential settings. In stratified analyses, cancer history was associated with all engagement categories among rural adults, including uptake only. That pattern suggests rural patients with prior cancer are not absent from the genetic testing pathway; they may be moving through it differently, with different entry points or less consistent provider-mediated discussion.
For clinicians, the distinction points toward how testing is initiated, not just whether it occurs. Rural adults may face different referral networks, fewer genetics specialists, longer travel burdens, or more fragmented continuity of care. Those pressures can shape whether a patient hears about testing during oncology care, primary care follow-up, or after the test has already been ordered.
Why the observed pattern matters biologically and clinically
Genetic cancer risk testing is not a detached administrative step. It sits at the intersection of tumor biology, inherited susceptibility, and cascade risk for relatives. A personal cancer history often serves as the clinical trigger for germline evaluation because the diagnosis may reflect an inherited mutation, particularly when the phenotype is early, unusual, or clustered in a family. Once that possibility enters the chart, the conversation should ideally connect diagnosis, treatment selection, and family counseling.
The split between discussion only and uptake only is especially informative. Discussion without uptake can reflect uncertainty, limited access, cost concerns, or competing treatment priorities. Uptake without documented discussion may reflect outside ordering channels, prior counseling, or survey limitations in how patients recall or classify the encounter. Either pattern matters because test completion alone does not ensure a patient received meaningful interpretation, post-test counseling, or follow-through on family implications.
What the rural uptake-only signal can and cannot mean
The rural uptake-only finding should be treated carefully. The interaction testing was model-level rather than outcome-specific, which means the statistical signal cannot be overread as proof of a unique rural mechanism for test completion without discussion. It does, however, justify closer scrutiny of how testing is delivered in rural settings and which clinical encounters are initiating it.
A rural patient may receive testing in oncology, a specialty clinic, or through a pathway that never reaches a genetics-focused conversation in the survey frame. Another possibility is that testing access is increasingly available through broader health system workflows, while the counseling component lags behind. Both possibilities have direct implications for informed consent, family communication, and the interpretation of a negative or positive result.
The study design also limits causal claims. Cross-sectional NHIS data can show association, not sequence. The direction of influence is clinically plausible but not temporally verified: cancer history likely prompts testing, yet the survey cannot distinguish whether testing was pursued because of the diagnosis itself, a family history recognized later, or a prior inherited risk evaluation that predates the cancer event.
Measurement gaps still separate access from understanding
The most actionable limitation is also the most revealing one: the survey could not capture the test source, ordering context, or provider involvement in detail. Those missing elements are central to understanding why some adults discuss testing without completing it, while others complete testing without a clearly documented discussion. A richer account would also clarify whether the test was ordered by oncology, primary care, gynecology, surgery, or a genetics specialist, and whether the result led to downstream counseling or family referral.
The numbers already suggest a substantial unmet opportunity. Nearly nine in ten adults reported no engagement at all, despite the growing clinical relevance of germline testing in cancer care. Among those with a personal cancer history, the testing pathway appears much more active, but the rural-stratified results imply that context shapes the route into care. For health systems, that means access metrics should not stop at test uptake. They should also track whether patients are being informed, counseled, and connected to the next step in risk assessment.
This study leaves one concrete question on the table: when rural adults with cancer history complete testing, are they reaching genetics care through a structured discussion, or through a more fragmented process that survey categories cannot fully capture? The answer will determine whether the observed uptake represents equitable access or simply a different route through the same bottleneck.